Compare Bank of Nova Scotia (BNS) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Nova Scotia vs McKesson Corporation — how do they compare? Bank of Nova Scotia trades at $89.04 (market cap $108.17B), while McKesson Corporation trades at $801.26 (market cap $94.06B). The key difference: Bank of Nova Scotia is the larger of the two by market cap, and Bank of Nova Scotia pays the higher dividend (3.61%). Which is the better fit depends on your goals.
| BNS | MCK | |
|---|---|---|
Market Cap | $108.17B | $94.06B |
Sector | Financials | Health |
52-Week High | $88.99 | $995.69 |
52-Week Low | $54.50 | $659.01 |
Dividend Yield | 3.61% | 0.41% |
Enterprise Value | — | $98.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bank of Nova Scotia (BNS) trades at $88.00, up 0.47% with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with Q2 2026 earnings beating expectations, revenue growth to $37.1B, and a healthy 24.86% net income margin. Recent acquisition of MapleMark Bank supports strategic growth initiatives while the dividend increase to $1.14 signals management confidence.
BNS presents a compelling investment case with consistent earnings beats, attractive dividend yield, and strategic expansion. However, elevated valuation multiples and macroeconomic sensitivity in the banking sector warrant caution. Analyst consensus remains positive with 53% buy ratings, though the stock trades near resistance levels requiring careful entry timing.
McKesson (MCK) trades at $812.28, up 0.78% with a bullish technical signal. The stock shows consistent earnings beats, with Q1 2026 EPS of $11.69 exceeding expectations. Revenue grew to $359.05B in 2025, though net margins remain thin at 1.18%. Analysts maintain strong buy consensus (80%) with a $932.83 price target. Recent news highlights growth in specialty pharma and oncology services, supporting positive momentum.
Outlook remains positive driven by earnings strength and sector tailwinds, but risks include policy changes and high liabilities. The stock offers value with a P/E of 21.16 and P/S of 0.25, though investors should monitor debt levels and execution risks amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Nova Scotia
Bank of Nova Scotia is a global financial services provider. The bank has five business segments: Canadian banking, international banking, global wealth management, global banking and markets, and other. It offers a range of advice, products, and services, including personal and commercial banking, wealth management and private banking, corporate and investment banking, and capital markets. The bank's international operations span numerous countries and are more concentrated in Central and South America.
Read more on BNS →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
